RFL - NYSE
Rafael Holdings, Inc.
$1.39
+7.0%Rafael Holdings, Inc. holds interests in clinical and early stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. The company operates in two segments, Pharmaceuticals and Real Estate. It engages in the leasing of a commercial office building, as well as an associated 800-car public garage; and development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company's lead drug candidate is CPI-613 (devimistat), which is being evaluated in various clinical studies, including two Phase III registrational clinical trials for the treatment of metastatic pancreatic cancer and r/r acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.
At a Glance
Live Snapshotrfl
Cash and Cash Equivalents
Last Annual Value
52.77M
3-Year CAGR
26%
5-Year CAGR
53%
10-Year CAGR
37%
Rafael Holdings, Inc. Competitors Analysis of Cash and Cash Equivalents
| Company | Cash and Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Rafael Holdings, Inc. NYSE:RFL | 52.77M | 34.9% | 46.4% | 36.6% | |
 Offerpad Solutions Inc. NYSE:OPAD | 43.02M | -17.3% | -24.0% | N/A | |
 Sachem Capital Corp. AMEX:SACH | 10.92M | -4.6% | -23.6% | 21.5% |
Rafael Holdings, Inc. Fair Value Envelope
Related Guides
Continue your RFL research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.